Avalo Therapeutics Company Insiders
| AVTX Stock | USD 10.13 0.48 4.97% |
Avalo Therapeutics employs about 19 people. The company is managed by 13 executives with a total tenure of roughly 45 years, averaging almost 3.0 years of service per executive, having 1.46 employees per reported executive. Break down of Avalo Therapeutics' management performance can provide insight into the company performance.
Avalo |
Avalo Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Avalo Therapeutics' future performance. Based on our forecasts, it is anticipated that Avalo will maintain a workforce of slightly above 19 employees by December 2024.Avalo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3064) % which means that it has lost $0.3064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Avalo Therapeutics' management efficiency ratios could be used to measure how well Avalo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.16 in 2024. Return On Capital Employed is likely to drop to -1.5 in 2024. At this time, Avalo Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 16.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 112 K in 2024.Common Stock Shares Outstanding is likely to rise to about 291.6 K in 2024, despite the fact that Net Loss is likely to grow to (72.1 M).
Avalo Therapeutics Workforce Comparison
Avalo Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,510. Avalo Therapeutics claims roughly 19.0 in number of employees contributing just under 2% to equities under Health Care industry.
Avalo Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avalo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avalo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Avalo Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-06-01 | 9.5 | 38 | 4 | 391,723 | 5,291,542 |
| 2021-06-01 | 24.0 | 24 | 1 | 6,810,910 | 0.00 |
| 2021-03-01 | 3.25 | 13 | 4 | 4,460,767 | 675,000 |
| 2020-06-01 | 4.6 | 23 | 5 | 4,066,483 | 205,373 |
| 2020-03-01 | 5.75 | 23 | 4 | 14,019,626 | 1,600,000 |
| 2019-09-01 | 24.0 | 24 | 1 | 3,008,319 | 3,246 |
| 2019-06-01 | 26.0 | 52 | 2 | 3,427,480 | 303,723 |
| 2018-12-01 | 33.3333 | 100 | 3 | 574,112 | 14,292,585 |
| 2018-09-01 | 20.0 | 40 | 2 | 4,632,350 | 2,540 |
| 2018-03-01 | 3.5 | 7 | 2 | 215,570 | 102,056 |
| 2017-12-01 | 17.0 | 17 | 1 | 86,551 | 1,270 |
| 2017-09-01 | 53.0 | 53 | 1 | 12,701,725 | 4,179 |
| 2017-06-01 | 26.0 | 26 | 1 | 29,764,334 | 0.00 |
| 2015-12-01 | 1.36 | 34 | 25 | 8,441,733 | 221,898,805 |
Avalo Therapeutics Notable Stakeholders
An Avalo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Avalo Therapeutics often face trade-offs trying to please all of them. Avalo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Avalo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Garry MD | President Board | Profile | |
| Christopher CPA | CFO relations | Profile | |
| Blake MD | Scientific Advisor | Profile | |
| Barbara Slusher | Founder Board | Profile | |
| Maxim CFA | VP Relations | Profile | |
| Stephen Thomas | VP Discovery | Profile | |
| Christopher Sullivan | Chief Officer | Profile | |
| Colleen Matkowski | Senior Assurance | Profile | |
| Lisa Hegg | Corporate Management | Profile | |
| Solomon MD | Founder Board | Profile | |
| MPH JD | Chief Officer | Profile | |
| Dino Miano | Senior Operations | Profile | |
| MD FACR | Chief Officer | Profile |
About Avalo Therapeutics Management Performance
The success or failure of an entity such as Avalo Therapeutics often depends on how effective the management is. Avalo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Avalo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Avalo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.01) | (3.16) | |
| Return On Capital Employed | (1.43) | (1.50) | |
| Return On Assets | (1.50) | (1.58) | |
| Return On Equity | (4.32) | (4.53) |
Please note, the imprecision that can be found in Avalo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Avalo Therapeutics. Check Avalo Therapeutics' Beneish M Score to see the likelihood of Avalo Therapeutics' management manipulating its earnings.
Avalo Therapeutics Workforce Analysis
Traditionally, organizations such as Avalo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Avalo Therapeutics within its industry.Avalo Therapeutics Manpower Efficiency
Return on Avalo Therapeutics Manpower
| Revenue Per Employee | 101.3K | |
| Revenue Per Executive | 148K | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 2.4M | |
| Working Capital Per Employee | 198.8K | |
| Working Capital Per Executive | 290.5K |
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.